Proposed Federal Cancer Research Cuts Raise Alarm in Medical Community

Highlights

• The Trump administration's budget proposal includes a nearly 40% cut to the NIH budget and a 37% reduction for the NCI.
• ASCO CEO Clifford Hudis warns the cuts would be “devastating” to cancer research progress and patient outcomes.
• ASCO stresses that federally funded cancer research remains the country's best investment in health innovation.
• ACS CAN highlights the direct link between sustained federal funding and medical breakthroughs that have led to over 18 million cancer survivors.
• Both organizations warn the cuts could reverse recent gains in reducing cancer death rates.

ASCO CEO Warns of Impact on Cancer Research Progress

The Trump administration's budget proposal, unveiled on May 30, includes significant funding cuts to the National Institutes of Health (NIH) and its National Cancer Institute (NCI). Clifford Hudis, M.D., CEO of the American Society of Clinical Oncology (ASCO), expressed grave concern over the potential consequences of these reductions. In an official statement, Dr. Hudis described the proposed cuts as “devastating to the pace and progress of cancer research in America” if implemented.

Dr. Hudis emphasized the importance of federally funded cancer research, stating, “ASCO maintains that federally funded cancer research is the single best investment our country has ever made.” He warned that “slashing federal research funding at a time when science is revolutionizing cancer care risks leaving millions of patients without the promise and potential of life-saving breakthroughs.”

Details of the Budget Proposal

The administration's budget suggests reducing the NCI's budget to approximately $4.5 billion, marking a roughly 37% cut from the previous year. More broadly, the NIH's overall budget would be trimmed by $18 billion, bringing the total to $27.9 billion—a nearly 40% reduction, according to summaries from the Department of Health and Human Services.

Industry Leaders Speak Out Against Cuts

Dr. Hudis voiced alarm over the drastic funding reductions, highlighting America's historical leadership in medical research. “America became the global leader in medical research and innovation through deliberate design and decades of intentional investment. Proposed funding cuts threaten all we have gained through this investment,” he stated.

He further underscored the urgency of maintaining U.S. scientific leadership, saying, “The U.S. cannot afford to abdicate its leadership in scientific innovation. The path to conquering cancer is to keep pushing science forward and ASCO will continue relentlessly defending and advocating for robust federal cancer research funding.”

American Cancer Society's Cancer Action Network Echoes Concerns

The American Cancer Society's Cancer Action Network (ACS CAN) also condemned the proposed budget cuts in a statement released on May 30. The network emphasized that these reductions still require Congressional approval before enactment.

ACS CAN highlighted the critical role of federal investment in cancer research over the past five decades. “For the past 50 years, every significant medical breakthrough, especially in the treatment of cancer, has been linked to sustained federal investment in research at NIH and NCI,” the organization stated. This investment has contributed to “over 18 million cancer survivors currently living in the U.S. today.”

The network warned that “these proposed cuts will lead to more suffering and death from cancer, reversing course on the downward trend in cancer death rates.”

Reference

[1]. https://www.whitehouse.gov/wp-content/uploads/2025/05/appendix_fy2026.pdf

[2]. https://www.hhs.gov/sites/default/files/fy-2026-budget-in-brief.pdf